

## ORIGINAL ARTICLE

# Glucagon receptor is required for long-term survival: A natural history study of the Mahvash disease in a murine model

Run Yu<sup>a,\*</sup>, Song-Guang Ren<sup>b</sup>, James Mirocha<sup>c</sup>

<sup>a</sup> Division of Endocrinology and Carcinoid and Neuroendocrine Tumor Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA

<sup>b</sup> Division of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, CA, USA

<sup>c</sup> Research Institute and General Clinical Research Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Received 16 April 2012; accepted 22 June 2012

Available online 28 August 2012

## KEYWORDS

Mahvash disease;  
Glucagon receptor;  
Murine model;  
Pancreatic  
neuroendocrine  
tumors

## Abstract

**Background and aim:** We have described a novel Mahvash disease of hyperglucagonemia and pancreatic neuroendocrine tumors (PNETs) associated with an inactivating glucagon receptor mutation, and identified the glucagon receptor-deficient ( $Gcgr^{-/-}$ ) mice as its murine model. We aim to elucidate the natural history of the rare Mahvash disease by long-term observation of the  $Gcgr^{-/-}$  mice.

**Materials and method:** Wild type (WT) ( $n=52$ ), heterozygous ( $n=127$ ), and  $Gcgr^{-/-}$  ( $n=56$ ) mice living under standard vivarium conditions were observed without specific treatments over 22 months. Autopsy was performed on dead animals.

**Results:** The WT and heterozygous mice did not exhibit any measurable differences. The  $Gcgr^{-/-}$  mice became progressively lethargic and cachexic after 12 months. Random glucose levels were stable in WT and heterozygous mice but decreased with age in the  $Gcgr^{-/-}$  mice. At the end of observation, 28/56  $Gcgr^{-/-}$ , 7/52 WT, and 24/127 heterozygous mice died. The survival curve of  $Gcgr^{-/-}$  mice began to separate from those of WT and heterozygous mice at 12 months and the survival difference widened with age. At 18 months, survival probability was 17% for  $Gcgr^{-/-}$  mice but 77% for WT and 81% for heterozygous mice. Autopsy revealed numerous PNETs up to 15 mm in diameter in most well-preserved  $Gcgr^{-/-}$  pancreata (17/20) but none in WT or heterozygous ones. Four  $Gcgr^{-/-}$  mice developed liver or subcutaneous metastasis.

**Conclusion:** The untreated Mahvash disease may cause cachexia, severe hypoglycemia, and early death. Patients with Mahvash disease need to undergo life-long surveillance for PNETs. Functional glucagon receptor is thus required for long-term survival.

© 2012 SEEN. Published by Elsevier España, S.L. All rights reserved.

\* Corresponding author.

E-mail address: [run.yu@cshs.org](mailto:run.yu@cshs.org) (R. Yu).

**PALABRAS CLAVE**

Enfermedad de Mahvash;  
Receptor de glucagón;  
Modelo murino;  
Tumors neuroendocrinos pancreáticos

## El receptor de glucagón es necesario para la supervivencia a largo plazo: Un estudio de la historia natural de la enfermedad de Mahvash en un modelo murino

**Resumen**

**Antecedentes y objetivo:** Hemos descrito la nueva enfermedad de Mahvash en la que existen hiperglucagonemia y tumores neuroendocrinos pancreáticos (TNEP) asociados con una mutación inactivante del receptor de glucagón, e identificado a los ratones con déficit del receptor de glucagón ( $Gcgr^{-/-}$ ) como su modelo murino. Nuestro objetivo era desentrañar la historia natural de la rara enfermedad de Mahvash mediante observación a largo plazo de ratones  $Gcgr^{-/-}$ .

**Materiales y métodos:** Se observó durante 22 meses a ratones silvestres (WT) ( $n = 52$ ), heterocigotos ( $n = 127$ ) y  $Gcgr^{-/-}$  ( $n = 56$ ) mantenidos en las condiciones habituales de un animalario sin recibir tratamientos específicos. Se practicaron autopsias a los animales muertos.

**Resultados:** No se observaron diferencias apreciables entre los ratones WT y los heterocigotos. Los ratones  $Gcgr^{-/-}$  mostraron letargia y caquexia progresiva al cabo de 12 meses. Los niveles de glucosa aleatorios eran estables en los ratones WT y heterocigotos, pero descendían con la edad en los ratones  $Gcgr^{-/-}$ . Al final de la observación habían fallecido 28/56 ratones  $Gcgr^{-/-}$ , 7/52 ratones WT y 24/127 ratones heterocigotos. La curva de supervivencia de los ratones  $Gcgr^{-/-}$  empezaba a separarse de las de los WT y heterocigotos a los 12 meses, y la diferencia en la supervivencia se ampliaba con la edad. La probabilidad de supervivencia de los ratones  $Gcgr^{-/-}$  a los 18 meses era del 17%, en comparación con el 77% y el 81% en los ratones WT y heterocigotos, respectivamente. La autopsia reveló numerosos TNEP de hasta 15 mm de diámetro en los páncreas mayoritariamente bien conservados de los ratones  $Gcgr^{-/-}$  (17/20), pero ninguno en los ratones WT o heterocigotos. Cuatro ratones  $Gcgr^{-/-}$  desarrollaron metástasis hepáticas o subcutáneas.

**Conclusión:** La enfermedad de Mahvash no tratada puede causar caquexia, hipoglucemia intensa y muerte temprana. Los pacientes con enfermedad de Mahvash tienen que someterse a vigilancia de por vida en busca de TNEP. En consecuencia, es necesario un receptor de glucagón funcional para la supervivencia a largo plazo.

© 2012 SEEN. Publicado por Elsevier España, S.L. Todos los derechos reservados.

**Introduction**

We have described a novel human disease (Mahvash disease) based on a patient who had extreme hyperglucagonemia but without glucagonoma syndrome, pancreatic  $\alpha$  cell hyperplasia and nesidioblastosis, and pancreatic neuroendocrine tumors (PNETs), associated with an inactivating glucagon receptor mutation (P86S).<sup>1-3</sup> The P86S mutant glucagon receptor exhibits abnormal subcellular localization and decreased glucagon binding; it also compromises glucagon-stimulated cAMP production and calcium signaling.<sup>2,4</sup> After our initial report,<sup>1</sup> similar pancreatic histology is also reported in a few other cases, but whether they are associated with glucagon receptor mutations is not clear.<sup>5,6</sup> The molecular mechanisms for those patients with unknown genetic causes have not been studied. All patients with the unique pancreatic histology do not have clinical or genetic evidence of multiple endocrine neoplasia syndrome type 1 (MEN1) or von Hippel-Lindau disease (VHL) which can involve pancreatic neuroendocrine microadenomatosis.<sup>7,8</sup> We further demonstrated that the glucagon receptor knockout ( $Gcgr^{-/-}$ ) mice are a faithful model of the human Mahvash disease.<sup>9,10</sup> In the  $Gcgr^{-/-}$  mice, hyperglucagonemia is severe but skin rash or diabetes is not present; islet hyperplasia and dysplasia become evident at 5–7 months, and PNETs developed with 100% penetrance at 10–12 months.

The natural history of the Mahvash disease is largely unknown. As the Mahvash disease is very rare, currently it is not possible to study the Mahvash disease in a large patient population. To study the natural history of the Mahvash disease, we have observed the  $Gcgr^{-/-}$  mice over 22 months. We demonstrate that the  $Gcgr^{-/-}$  mice exhibit multiple abnormalities and die much earlier than the WT or heterozygous controls. PNETs continuously emerge and relentlessly grow in the  $Gcgr^{-/-}$  mice. The natural history of the Mahvash disease shown in this murine model indicates that functional glucagon receptor is required for long-term survival.

**Materials and methods****Animals**

The  $Gcgr^{-/-}$  mice generated and provided by Pfizer Global Research and Development were described previously.<sup>9</sup> The colony propagated at Cedars-Sinai Medical Center was pure-bred DBA1/lacJ strain.<sup>10</sup> Heterozygous parents were bred to produce all animals studied, and wild type (WT) and heterozygous littermates used as controls for the  $Gcgr^{-/-}$  mice. Animals were raised in a 12-h dark/light cycle and fed with standard chow ad libitum. As there was no sexual dimorphism in the described abnormalities, both male and female mice were used, and data on them analyzed together. All

animals were rounded daily by vivarium staff and carefully examined weekly by the investigators for health and signs of diseases after 12 months. Periodically, animals were weighed and random glucose levels (defined as the glucose levels in tail-cut blood of free-feeding mice during the day time) measured by a glucometer. Minor lesions were monitored or treated symptomatically. Dead animals were stored at 4°C and autopsied as early as possible. Missing animals (2 WT, 6 heterozygous, and 4 *Gcgr*<sup>-/-</sup>) were presumed dead and the date on which they were found missing was used as date of death; the death was confirmed orally by vivarium staff in a few cases but the cadavers were disposed and not available for autopsy. When the vivarium staff and the investigators judged a mouse moribund or significantly suffering from non-lethal lesions, the animal was euthanized by CO<sub>2</sub> asphyxiation after being weighed and random glucose levels measured. During autopsy, the visceral organs in the chest, abdomen, and pelvis were examined in detail and all organs with gross abnormalities were harvested and fixed in 10% neutral formalin. Four 18-month healthy-appearing WT and heterozygous mice were also euthanized to screen for pancreatic neuroendocrine tumors. Experiments were approved by the Cedars-Sinai Institutional Animal Care and Use Committee.

### Histology, immunostaining, and microscopy

Ten 5- $\mu$ m paraffin sections per pancreas, 100  $\mu$ m apart on the cross sections, were stained with hematoxylin and eosin (H&E) and histology examined. Dysplastic islets were identified by the blood islands and abundant stromal tissue and pancreatic neuroendocrine tumors (PNETs) by the trabecular cell growth pattern. For immunofluorescent staining, 5- $\mu$ m pancreatic sections were deparaffinized, rehydrated, and incubated with rabbit anti-glucagon and guinea pig anti-insulin antibodies (Dako, Carpinteria, CA, USA), followed by FITC-labeled anti-rabbit and rhodamine-labeled anti-guinea pig secondary antibodies. All sections were counter-stained with Hoechst 33342. Stained pancreatic sections were examined with an Olympus IX2-SP microscope with both bright field capacity and fluorescence filters. Digital photographs were acquired with a MegnaFire camera (Olympus, Center Valley, PA, USA).

### Data analysis

The changes of body weight and blood glucose levels over time were estimated by linear regression and the significance of the difference of the slopes was determined by a slope-by-group interaction term. Probability of survival was estimated by the Kaplan-Meier method and statistical significance calculated by the log-rank analysis. Student's *t*-test was used to compare the means of continuous parameters between 2 groups. SD was used to describe the variability of continuous data. Fisher's exact test was used to compare the frequencies of a parameter between 2 groups.

## Results

### Growth and glycemia of old *Gcgr*<sup>-/-</sup> mice

Fifty-two WT, 127 heterozygous, and 56 *Gcgr*<sup>-/-</sup> mice were observed for a maximum of 22 months (Table 1). Some animals were observed for shorter than 22 months. We have previously described that the *Gcgr*<sup>-/-</sup> mice fail to gain weight after 3 months but the WT and heterozygous mice continue to grow until 12 months.<sup>10</sup> After 12 months, all 3 groups of mice gradually lost weight at about the same rate. The *Gcgr*<sup>-/-</sup> mice remained lighter throughout life; at 18 months and later, they were 33% lighter than the WT and heterozygous mice (body weight  $21.9 \pm 2.1$  g for *Gcgr*<sup>-/-</sup>,  $32.7 \pm 6.8$  g for WT, and  $31.1 \pm 4.3$  g for heterozygous mice,  $p < 0.001$ ) (Fig. 1). Random blood glucose levels were stable in the WT or heterozygous group after 12 months but decreased over time in the *Gcgr*<sup>-/-</sup> mice ( $0.22$  mg/dL/day,  $p < 0.0001$ ) (Fig. 1). The random glucose levels were very low in the *Gcgr*<sup>-/-</sup> mice after 18 months ( $33.6 \pm 14.3$  mg/dL vs.  $127.2 \pm 20.5$  mg/dL in the WT and  $123.8 \pm 15.2$  mg/dL in the heterozygous mice,  $p < 0.0001$ ). The lowest random blood glucose levels in the WT or heterozygous mice were 77 mg/dL at any time. Interestingly, although most *Gcgr*<sup>-/-</sup> mice with blood glucose levels  $< 20$  mg/dL died within days, a few mice remained alive for up to 3 months.

### Survival of the *Gcgr*<sup>-/-</sup> mice

After 12 months, the *Gcgr*<sup>-/-</sup> mice became progressively lethargic and cachexic and some died, while the WT and heterozygous mice mostly remained active and maintained body weight. During the 22-month period, 7 of 52 WT, 24 of 127 heterozygous, and 28 of 56 *Gcgr*<sup>-/-</sup> mice died or were euthanized due to moribund appearance during the observation period (Table 1). Kaplan-Meier analysis showed that while WT and heterozygous mice did not exhibit difference in survival, the *Gcgr*<sup>-/-</sup> mice died significantly earlier (Fig. 2). The survival curve of the *Gcgr*<sup>-/-</sup> mice began to separate from those of WT and heterozygous mice at 12 months (survival probability 79%, 96%, and 92%, respectively) and the survival difference became progressively larger with age. At 18 months, the survival probability was 17% for the *Gcgr*<sup>-/-</sup> mice but 77% for the WT and 81% for heterozygous mice. Thus, most deaths in the *Gcgr*<sup>-/-</sup> mice occurred between 12 and 18 months. No *Gcgr*<sup>-/-</sup> mice survived beyond 22 months; in contrast, the WT and heterozygous mice had  $> 60\%$  surviving probability beyond 22 months. As expected, the mean age of surviving *Gcgr*<sup>-/-</sup> mice was  $\sim 4.5$  months younger than that of surviving WT or heterozygous animals (Table 1). Univariate analysis of the relationship between hypoglycemia and *Gcgr*<sup>-/-</sup> mice mortality showed that the mortality was much higher in mice with random glucose levels  $< 60$  mg/dL than in those with  $\geq 60$  mg/dL (83% vs. 47%,  $p < 0.05$ ).

### Autopsy findings

The cadavers were available for autopsy in 5 WT, 16 heterozygous, and 24 *Gcgr*<sup>-/-</sup> mice. The cadavers were severely autolysed and no discerning gross features could be

**Table 1** Fate of all animals at the time of writing.


	WT	Heterozygous	Gcgr <sup>-/-</sup>
Numbers observed, <i>n</i> (F/M)	52 (24/28)	127 (67/60)	56 (28/28)
Euthanized for experiments <sup>a</sup> , <i>n</i> (F/M)	19 (9/10)	36 (20/16)	15 (8/7)
Euthanized for non-lethal lesions or birth traumas, <i>n</i> (F/M)	6 (0/6)	7 (3/4)	1 (1/0)
Euthanized for non-lethal lesions or birth traumas, mean age (SD), months	8.8 (2.1)	10.7 (3.8)	7.4
Died naturally or euthanized for moribund appearance <sup>b</sup> , <i>n</i> (F/M)	7 (4/3)	24 (8/16)	28 (14/14)
Died naturally or euthanized for moribund appearance, mean age (SD), months	13.8 (4.0)	14.3 (5.5)	14.0 (3.4)
Probable causes of death, <i>n</i>	3 (1 diabetes, 1 pelvic tumor, 1 abnormal kidney)	6 (2 pelvic tumor, 1 adrenal tumor, 1 abnormal liver, 1 anasarca, 1 ascites)	17 (all PNET). 13 mice with PNET also had hypoglycemia (<60 mg/dL)
Causes of death unclear, <i>n</i>	4	18	11
Alive, <i>n</i> (F/M)	20 (11/9)	60 (36/24)	12 (5/7)
Alive, mean age (SD), months	16.9 (3.8)	17.4 (4.1)	12.6 (2.7) <sup>c</sup>

WT, wild type; F, female; M, male; *n*, number.

<sup>a</sup> Including 10 WT, 25 heterozygous, and 10 Gcgr<sup>-/-</sup> mice reported in Ref. 10.

<sup>b</sup> Including 4 Gcgr<sup>-/-</sup> mice reported in Ref. 10.

<sup>c</sup>  $p < 0.002$  comparing the age of Gcgr<sup>-/-</sup> and WT or heterozygous mice.



**Figure 1** Growth and glycemia of older Gcgr<sup>-/-</sup> mice. Body weight and blood glucose levels were measured periodically in 52 wild type (WT), 127 heterozygous (HZ), and 56 Gcgr<sup>-/-</sup> mice (KO) over 22 months. (Upper panels) Body weight from 12 to 22 months. (Lower panels) Random blood glucose levels from 12 to 22 months. The straight lines stand for the results of linear regression of body weight or blood glucose levels versus time. The linear regression equation and *R* squared value are shown for each graph.


**Table 2** Summary of autopsy findings of 20  $Gcgr^{-/-}$  mice that died naturally or were euthanized due to moribund appearance.

ID	Age at death (months)	Sex	Autopsy findings	3 Largest PTs (mm)	Metastasis
33	10.3	M	Multiple PTs	5/2/2	No
79 <sup>a</sup>	10.4	M	No gross abnormality	NA	No
27 <sup>a</sup>	10.5	M	No gross abnormality	NA	No
44	11.3	M	1 PT	1/NA/NA	No
39	11.5	M	Multiple PTs	7/3/2	Liver (miliary)
93	12.2	F	1 PT	4.1/NA/NA	No
168	13.2	M	Multiple PTs	5/3/3	No
189	14.5	F	Numerous PTs	4/3/3	No
97	14.7	F	1 PT	5/NA/NA	No
89	14.7	F	Multiple PTs	5/3/2	Chest wall (10-mm)
155	15.1	M	Multiple PTs	3/1/1	No
100	15.2	F	Multiple PTs	12/5/3	No
184	15.5	M	Multiple PTs	15/3/3	No
188	15.7	F	Multiple PTs	15/3/2	Liver (numerous, largest one 5-mm)
67	16.4	M	Multiple PTs	10/3/3	No
147	17.1	M	Numerous PTs	6/4/2	No
113	17.9	M	Numerous PTs	7/5/4	No
118	19.5	M	Multiple PTs	5/4/3	No
111	20.5	F	Multiple PTs	15/10/7	Liver (numerous, largest one 6-mm)
91	21.6	F	Numerous PTs	6/5/4	No

Mice 33, 27, 44, and 39 were partly reported in Ref. 10. PT, pancreatic tumors; F, female; M, male; NA, not applicable.

<sup>a</sup> Micro-PNETs were identified in mouse 79 (and 27 as partly reported in Ref. 10) by histology.

examined in 1 WT, 5 heterozygous, and 4  $Gcgr^{-/-}$  mice. Overall, 4 WT, 11 heterozygous, and 20  $Gcgr^{-/-}$  mice gave satisfactory autopsy results (Table 2). The cause of death was apparent on anatomical grounds in 2 WT,




**Figure 2** Kaplan-Meier survival curve of wild type (WT) (green), heterozygous (HZ) (red), and  $Gcgr^{-/-}$  (KO) (blue) mice. The overall log-rank  $p < 0.0001$  when all 3 groups were calculated simultaneously;  $p = 0.804$  comparing WT and HZ survival;  $p < 0.0001$  comparing WT and KO survival or comparing HZ and KO survival separately.

6 heterozygous, and 17  $Gcgr^{-/-}$  mice; in the remainder of animals, no gross abnormalities or only small pancreatic tumors (in  $Gcgr^{-/-}$  mice) were seen (Tables 1 and 2). One WT mouse had severe diabetes for unclear reason which was likely the cause of death. There was no evidence of diabetes in the remaining 51 WT mice. In all cases, gross pancreatic lesions were not found in any WT or heterozygous mice at autopsy but most (17/20, 85%) discernable  $Gcgr^{-/-}$  pancreata harbored numerous pancreatic tumors of various sizes, some of which were so large (e.g. 15 mm) that the normal pancreas structure was severely distorted (Fig. 3). The total tumor mass comprised ~10–20% of body weight in some cadavers. Gross liver metastasis was found in 3  $Gcgr^{-/-}$  mice with larger pancreatic neuroendocrine tumors (PNETs) (Table 2, Fig. 3); a bulky subcutaneous metastasis was seen in another. All other visceral organs of the  $Gcgr^{-/-}$  mice appeared normal at autopsy. Thirteen of the 17 mice with gross PNETs also had hypoglycemia ( $<60$  mg/dL) (Table 1), which was associated with higher mortality (see above).


### Pancreatic histology

To examine whether older WT and heterozygous mice harbor abnormal islets or grossly inapparent PNETs, 4 WT and 4 heterozygous healthy-appearing 18-month-old mice (2 females and 2 males in each group) were euthanized and their pancreata compared with those of 4  $Gcgr^{-/-}$  mice at 15-month (2), 17-month (1), and 18-month (1). Compared with their  $Gcgr^{-/-}$  counterparts ( $815 \pm 309$  mg),





**Figure 3** Autopsy findings of  $Gcgr^{-/-}$  mice that died naturally or were euthanized due to moribund appearance. (A) Normal wild type (WT) and heterozygous (HZ) pancreata at 18 months are shown for comparison. (B)  $Gcgr^{-/-}$  (KO) pancreata at 17 months (left) and 18 months (right). Note the multiple pancreatic neuroendocrine tumors (PNETs) of various sizes dotting the pancreata. (C–E) Multiple bulky pancreatic tumors from 3  $Gcgr^{-/-}$  mice. (F) A large, metastatic subcutaneous PNET with central degeneration. (G) Numerous metastatic PNETs in the liver. Large arrows, large PNETs; and small arrows, small PNETs. Ruler: in cm.



**Figure 4** Histology of pancreas and pancreatic tumors. (A–C) Islet histology of wild type (WT) and heterozygous (HZ) mice at 18 months, and  $Gcgr^{-/-}$  mice (KO) at 15 months. Sections were stained with hematoxylin and eosin. (D–F) Histology of each of the gross lesions shown in Fig. 3D–F, respectively. Note the typical trabecular pattern of neuroendocrine tumor cells. Bar, 100  $\mu$ m.

the WT ( $314 \pm 24$  mg) and heterozygous ( $297 \pm 57$  mg) pancreata were much smaller ( $\sim 2.6$ -fold,  $p < 0.01$ ). Multiple sections of the 18-month-old WT and heterozygous pancreata showed normal endocrine and exocrine components without any evidence of islet dysplasia or micro-PNETs (Fig. 4). In comparison, similar sections of the  $Gcgr^{-/-}$  pancreata showed numerous dysplastic islets, microadenomas, or PNETs (Fig. 4), which suggests that new PNETs continuously develop even in older animals. Immunostaining of 17 PNETs of various sizes from 8 randomly picked older

$Gcgr^{-/-}$  mice showed that most PNETs were glucagonomas (14/17) and 2/17 were negative for either glucagon or insulin. No pure insulinomas were found but 1 small PNET was a mixed glucagonoma/insulinoma (expressing both glucagon and insulin in the same tumor cells).

## Discussion

The role of animal models in the study of human diseases, especially rare diseases, is increasingly recognized. The

Gcgr<sup>-/-</sup> mice were originally created to examine the effect of glucagon signaling on glycemia regulation.<sup>9</sup> There was no literature on similar human diseases available to us when we first reported the syndrome of the Mahvash disease.<sup>1</sup> The striking similarities between the phenotypes of the Mahvash disease and the Gcgr<sup>-/-</sup> mice prompted us to sequence the glucagon receptor gene in a patient with the Mahvash disease which led to the discovery of a homozygous inactivating P86S mutation in the glucagon receptor.<sup>2</sup> Further investigation of the Gcgr<sup>-/-</sup> mice confirms that they develop pancreatic neuroendocrine tumors (PNETs) with 100% penetrance at middle age.<sup>10</sup> In the current work, we have performed a natural history study in the Gcgr<sup>-/-</sup> mice, a model of the Mahvash disease, to understand the natural course of untreated Mahvash disease.

Our results show that the Gcgr<sup>-/-</sup> mice are less healthy and die prematurely. As all animals were littermates, lived in standard vivarium conditions, were fed with standard chows, and did not receive any specific treatments, their health and survival likely reflect the natural effects of deficient or inactive glucagon receptor, the cause of the Mahvash disease. The cachexia is probably a consequence of both decreased oral intake, as previously reported,<sup>11</sup> and pancreatic PNET tumor burden which may compromise nutrient absorption by disrupting the normal pancreas structure and may consume large amounts of nutrients themselves. Hypoglycemia is another prominent abnormality of the Gcgr<sup>-/-</sup> mice which is associated with higher mortality. The mechanisms for the progressive hypoglycemia in older animals are not clear. The random glucose levels of young Gcgr<sup>-/-</sup> mice are somewhat normal but lower than those in WT or heterozygous mice,<sup>10</sup> consistent with the loss of hyperglycemic function of glucagon. It appears that some aspects of aging worsen hypoglycemia in the Gcgr<sup>-/-</sup> mice. The remarkable hypoglycemia is unlikely caused by insulinoma, as hypoglycemia was present in all old animals but only 1 had a mixed glucagonoma/insulinoma. In patients with the Mahvash disease, it might be advisable to maintain normal body weight and monitor blood glucose levels to avoid cachexia and hypoglycemia.

The most important abnormality exhibited by the Gcgr<sup>-/-</sup> mice is the much reduced survival manifesting after 12 months. The reduced survival must be caused by glucagon receptor deficiency as the absence or presence of glucagon receptor was the only genetic difference between the Gcgr<sup>-/-</sup> mice and the WT and heterozygous littermates, and all the mice lived in the same environment. What are the underlying mechanisms for the reduced survival? Besides cachexia and hypoglycemia, the Gcgr<sup>-/-</sup> mice are known to exhibit other gross abnormalities such as placental insufficiency, increased in utero mortality, decreased fetal weight, and poor vision, some or all of which could contribute to the reduced survival.<sup>12-14</sup> In addition, the Gcgr<sup>-/-</sup> mice also have several metabolic abnormalities such as maladaptive metabolic adjustment to fasting, increased circulatory levels of amino acids, cholesterol, and bile acid, and high risks of fatty liver.<sup>15-17</sup> Those abnormalities need to be confirmed in patients with the Mahvash disease before their clinical significance is assessed.

We show that PNETs continuously develop and relentlessly grow as the Gcgr<sup>-/-</sup> mice age. The mechanisms for

PNET pathogenesis are not clear but may involve abnormal subcellular localization of menin.<sup>10</sup> As the Gcgr<sup>-/-</sup> mice do not have glucagon receptor, hyperglucagonemia and hyperactivity of glucagon signaling unlikely contribute to PNET pathogenesis. Several lines of evidence suggest that PNETs contribute to the early death of Gcgr<sup>-/-</sup> mice. First, gross PNETs were found at autopsy in most Gcgr<sup>-/-</sup> mice but not in any WT or heterozygous ones. Second, the PNET tumor burden was significant as evidenced by the large numbers and sizes of PNETs in the pancreas found at autopsy of most Gcgr<sup>-/-</sup> mice. Third, the extensive liver metastasis in some Gcgr<sup>-/-</sup> mice likely cause abnormal liver function and contribute to the mortality in those animals. Fourth, untreated human sporadic PNETs are lethal.<sup>18,19</sup> Last, no other gross visceral abnormalities were found in the dead or moribund Gcgr<sup>-/-</sup> mice that can explain their death. As it is not practical to do detailed histological studies of all visceral organs and we did not examine the central nervous system, we cannot rule out that potential lesions in those organs or systems also contribute to the early death of Gcgr<sup>-/-</sup> mice. In addition, hypoglycemia was present in most mice with gross PNETs and associated with higher mortality; the specific contribution of PNETs in the death of Gcgr<sup>-/-</sup> mice is thus unclear and requires further study. Interestingly, transdifferentiation from glucagonoma to insulinoma does not develop in old Gcgr<sup>-/-</sup> mice, in contrast to that in the mice with  $\alpha$  cell specific deletion of menin, which also exhibit  $\alpha$  cell hyperplasia and glucagonomas but the glucagonomas transdifferentiate into insulinomas as the animals grow older.<sup>20</sup> The continuous emergence and growth of PNETs in the Gcgr<sup>-/-</sup> mice indicate that patients with the Mahvash disease need to undergo imaging surveillance for early detection of clinically significant PNETs. All the findings from the Gcgr<sup>-/-</sup> mice need to be tested in patients with the Mahvash disease. Currently, detailed natural history of the Mahvash disease cannot be satisfactorily studied in humans due to its recent discovery and slow clinical progression.

Finally, our data suggest that glucagon antagonism as an experimental means of diabetes treatment needs long-term study to confirm its safety. Glucagon antagonism is a reasonable approach to treat diabetes but has been associated with reversible hyperglucagonemia and pancreatic  $\alpha$  cell hyperplasia, a phenotype resembling that in young Gcgr<sup>-/-</sup> mice, raising concerns for the risk of PNETs after long-term use.<sup>21,22</sup> It should be emphasized that glucagon receptor antagonism starting at adulthood is different from glucagon receptor deficiency since conception and pharmacological inhibition of glucagon signaling may prove to be safe after long-term studies.

In summary, the Gcgr<sup>-/-</sup> mice help delineate the natural history of the Mahvash disease and suggest that untreated Mahvash disease entails cachexia, hypoglycemia, large PNET tumor burden, and early death. These findings may guide clinical management of patients with the Mahvash disease. Our study also demonstrates that functional glucagon receptor is indispensable for health and life.

## Funding

This study was supported by NIH grant DK071870 (R.Y.) and Cedars-Sinai Medical Center.

## Conflicts of interest

The authors have no conflicts of interest to declare.

## Acknowledgement

The authors thank Pfizer Global Research and Development for providing the *Gcgr*<sup>-/-</sup> mice.

## References

1. Yu R, Nissen NN, Dhall D, Heaney AP. Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas. *Pancreas*. 2008;36:428–31.
2. Zhou C, Dhall D, Nissen NN, Chen CR, Yu R. Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. *Pancreas*. 2009;38:941–6.
3. Ouyang D, Dhall D, Yu R. Pathologic pancreatic endocrine cell hyperplasia. *World J Gastroenterol*. 2011;17:137–43.
4. Yu R, Wawrowsky K, Zhou C. A natural inactivating mutant of human glucagon receptor exhibits multiple abnormalities in processing and signaling. *Endocrinol Nutr*. 2011;58:258–66.
5. Henopp T, Anlauf M, Schmitt A, Schlenger R, Zalatnai A, Couvelard A, et al. Glucagon cell adenomatosis: a newly recognized disease of the endocrine pancreas. *J Clin Endocrinol Metab*. 2009;94:213–7.
6. Otto AI, Marschalko M, Zalatnai A, Toth M, Kovacs J, Harsing J, et al. Glucagon cell adenomatosis: a new entity associated with necrolytic migratory erythema and glucagonoma syndrome. *J Am Acad Dermatol*. 2011;65:458–9.
7. Anlauf M, Schlenger R, Perren A, Bauersfeld J, Koch CA, Dralle H, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. *Am J Surg Pathol*. 2006;30:560–74.
8. Corcos O, Couvelard A, Giraud S, Vullierme MP, Dermot O'Toole, Rebours V, et al. Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological and genetic features. *Pancreas*. 2008;37:85–93.
9. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD. Glycemic control in mice with targeted disruption of the glucagon receptor gene. *Biochem Biophys Res Commun*. 2002;290:839–43.
10. Yu R, Dhall D, Nissen NN, Zhou C, Ren SG. Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice. *PLoS One*. 2011;6:e23397.
11. Conarello SL, Jiang G, Mu J, Li Z, Woods J, Zycband E, et al. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. *Diabetologia*. 2007;50:142–50.
12. Vuguin PM, Kedees MH, Cui L, Guz Y, Gelling RW, Nejathaim M, et al. Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. *Endocrinology*. 2006;147:3995–4006.
13. Ouhilal S, Vuguin P, Cui L, Du XQ, Gelling RW, Reznik SE, et al. Hypoglycemia, hyperglucagonemia, and fetoplacental defects in glucagon receptor knockout mice: a role for glucagon action in pregnancy maintenance. *Am J Physiol Endocrinol Metab*. 2012;302:E522–31.
14. Umino Y, Everhart D, Solessio E, Cusato K, Pan JC, Nguyen TH, et al. Hypoglycemia leads to age-related loss of vision. *Proc Natl Acad Sci U S A*. 2006;103:19541–5.
15. Longuet C, Sinclair EM, Maida A, Baggio LL, Maziarz M, Charon MJ, et al. The glucagon receptor is required for the adaptive metabolic response to fasting. *Cell Metab*. 2008;8:359–71.
16. Yang J, MacDougall ML, McDowell MT, Xi L, Wei R, Zavadoski WJ, et al. Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes. *BMC Genomics*. 2011;12:281.
17. Berglund ED, Lustig DG, Baheza RA, Hasenour CM, Lee-Young RS, Donahue EP, et al. Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver. *Diabetes*. 2011;60:2720–9.
18. Verbeke CS. Endocrine tumours of the pancreas. *Histopathology*. 2010;56:669–82.
19. Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. *Langenbecks Arch Surg*. 2011;396:273–98.
20. Lu J, Herrera PL, Carreira C, Bonnavion R, Seigne C, Calender A, et al. Alpha cell-specific *Men1* ablation triggers the trans-differentiation of glucagon-expressing cells and insulinoma development. *Gastroenterology*. 2010;138:1954–65.
21. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. *J Clin Invest*. 2012;122:4–12.
22. Bagger JI, Knop FK, Holst JJ, Vilsbøll T. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. *Diabetes Obes Metab*. 2011;13:965–71.